Pfizer restructures R&D, elevates Oncology as standalone unit; CDO William Pao departing Aug 15

PFIZER INC

Pfizer restructures R&D, making Oncology a standalone unit; Dr. Chris Boshoff becomes Chief Oncology R&D Officer, EVP.
Dr. William Pao, Chief Development Officer, EVP, role eliminated; he will depart effective August 15, 2023.
Severance includes one year base salary and target bonus, two years welfare benefits, vesting of sign-on awards.
Reorganization driven by planned investment in Oncology, including proposed acquisition of Seagen Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William Pao

Chief Development Officer, Executive Vice President

PFE · PFIZER INC

Effective: 2023-08-15
Filed: July 27, 2023, 7:59 PM ET

As a result of this reorganization, the role held by Dr. William Pao, Chief Development Officer, Executive Vice President, is being eliminated and he will leave the Company effective August 15, 2023.

Role change

Chris Boshoff

Chief Oncology Research and Development Officer, Executive Vice President

PFE · PFIZER INC

Effective: 2023-07-27
Filed: July 27, 2023, 7:59 PM ET

Effective immediately, Dr. Chris Boshoff, currently Chief Development Officer – Oncology, will become Chief Oncology Research and Development Officer, Executive Vice President

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Pao departed as Chief Development Officer, Executive Vice President at PFIZER INC.

Action: departed
Role: Chief Development Officer, Executive Vice President

Exact text from the filing

As a result of this reorganization, the role held by Dr. William Pao, Chief Development Officer, Executive Vice President, is being eliminated and he will leave the Company effective August 15, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Boshoff was appointed as Chief Oncology Research and Development Officer, Executive Vice President at PFIZER INC.

Action: appointed
Role: Chief Oncology Research and Development Officer, Executive Vice President

Exact text from the filing

Effective immediately, Dr. Chris Boshoff, currently Chief Development Officer – Oncology, will become Chief Oncology Research and Development Officer, Executive Vice President

View on SEC.gov

PFIZER INC filing history →

Source: SEC EDGAR

accession 0000078003-23-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.